Arnon Aharon

Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel.

Thrombotech Ltd. is an Israel-based biotechnological company that is based on years of cutting-edge thrombotic research at the Hadassah Medical Center in Jerusalem. Thrombotech developed a peptide called THR-18, which allows the existing thrombolytic stroke medication to easily dissolve blood clots, extending its short therapeutic time window and diminishing life-threatening side effects. The company was founded in 2000 and is headquartered in Rehovot, Israel.

ProMining Therapeutics Ltd. provides biopharmaceutical research and development services. It is an early-stage biopharmaceutical research and development company engaged in the discovery and development of novel oral, small-molecule drugs for treatment of cancer, inflammation, chronic pain, and cardiovascular and viral diseases. The company was founded in 2011 and is headquartered in Nes Ziona, Israel.